Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial

Dow Jones03-28

By Stephen Nakrosis

Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.

In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71.

Portage said the data showed both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma.

The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7.

Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

March 27, 2025 18:02 ET (22:02 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522558220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-28 06:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522558220","market":"other","top_or_hot":-1,"title":"Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model. \n</p>\n<p>\n  In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71. \n</p>\n<p>\n  Portage said the data showed  both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. \n</p>\n<p>\n  The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7. \n</p>\n<p>\n  Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2025 18:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPortage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-28 06:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model. \n</p>\n<p>\n  In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71. \n</p>\n<p>\n  Portage said the data showed  both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. \n</p>\n<p>\n  The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7. \n</p>\n<p>\n  Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2025 18:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PORT","symbol_name":"SOUTHPORT ACQ CORP A","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522558220","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522558220","pubTimestamp":1743112920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71.Portage said the data showed  both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma.The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7.Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PORT":"SOUTHPORT ACQ CORP A","BK4139":"生物科技"},"translate_title":"PORT-7肿瘤治疗试验结果公布后，Portage Biotech股价上涨一倍多","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PORT":1,"PRTG":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model. \n\n\n  In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71. \n\n\n  Portage said the data showed  both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. \n\n\n  The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7. \n\n\n  Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 18:02 ET (22:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522558220","isCrawlerRequest":true}